1. Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines
Dr. Brian W Tempest
Pharmaceuticals & Global Health
Sussex University Conference Centre , Brighton, UK
19 July 2013

2. Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade.
Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until He was then Chief Mentor and Non Executive Director until 2008 when he retired. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also worked for Glaxo as Regional Director Far East and Regional Director Middle East & Africa from 1985 to 1992.
Brian has worked in the Pharmaceutical Industry for the last 41 years and has managed Healthcare businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India. He has also led many sessions at Investor Meetings held around the world.
He is now Independent Chairman of Religare Capital Markets PLC , a Non Executive Director of Fortis Healthcare the leading Asian Healthcare Company, a Non Executive Director of SRL the largest Indian Diagnostic Company and a Non Executive Director of Glenmark Pharmaceuticals. He is a member of the SCRIP Global awards panel and is on the Editorial Board of the Journal of Generic Medicines. Brian speaks at global conferences and more information on these presentations can be found on his website
Brian has a PhD in Polymer Chemistry from Lancaster University in 1971 and in 2009 he became Chairman of the Advisory Board for the Lancaster University Management School, UK. He is a Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman and Senior Partner of Hale & Tempest Co Ltd

3. Healthcare costs versus GDP & Wages

4. Everybody Concerned about Health Costs

5. Increasing Generics & Biosimilars

6. A Slide from a UK Headhunter

7. Pharma in Crisis Source: Pharmatimes February 2013

8. Generics versus Big Pharma

9. Patent Cliff to 2018 source: Evaluate Pharma, Sandoz

10. Top 25 Global Generic Companies Source: Generics Bulletin 10 June 2011

11. Products Going Off Patent in 2015 $33b Source: Evaluate Pharma 14 February 2013

12. The Teva Future – Standing Still Source: RBC Capital 12 December 2012

13. Global footprint of Watson/Actavis – excluding most of the developing world

14. Indian Generic Cos continue to grow Source: Pharmatimes World News Feb 5 2013
Many Indian Companies in 2013 showing a sales growth of >20%
Indian Pharma Exports around the World have shown a %CGR of +19% in sales
New Product Pipeline in USA ANDAs shows approvals from India in 2012 was 37% with 178 out of a total of 476 and in % with 144 out of 431
New ANDA filings of ANDAs in the USA from India indicate 51% in 2011 and 49% in 2010

15. India’s First Compulsory Licence after 3 years at a high price Source : Economic Times 13 March 2012

16. More CLs on the way in India Source: 29 March 2013

17. India Patent dismissed for Evergreening Source: Financial Express 2 April 2013

18. Anti Cancer Drugs At Delhi Airport Source: New Delhi Airport 28 March 2013

19. But Indian Price Cuts source: Hindustan Times 20 June 2013

20. Aggressive EU-India Bilateral FTA Source: ET 27 March 2013

21. The Future of IP? In 2012 Big pharma had the best NCE year since 1997
There are $230b sales going off patent in but only half will be replaced by generics owing to biologics
Big Pharma is finding the BRICS markets tough
More CLs likely from the BRICS countries owing to evergreening or a very high price limiting access
Do all patents need to be 20 years? The first USA patent law in 1790 was for 14 years.
What is the point of a patent if only the rich can use it?

22. Thank You